Multiple sclerosis treatments funding proposal in New Zealand
New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis (MS), including two new treatments that are not currently funded – natalizumab and fingolimod.
In summary, this proposal would result, from November 1, in:
- natalizumab (Tysabri), supplied by USA-headquartered Biogen Idec (Nasdaq: BIIB), and fingolimod (Gilenya), supplied by Swiss pharma major Novartis (NOV: N), being funded in the community and in District Health Board (DHB) hospitals subject to restrictions; and
- changes to the restrictions for funded access, in the community and in DHB hospitals, for interferon beta-1-alpha (Avonex, also from Biogen Idec), interferon beta-1-beta (Betaferon, from Bayer) and glatiramer acetate (Copaxone, from Teva Pharmaceutical Industries).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze